Humanin

Humanin Molecular Structure & Chemical Properties

Humanin peptide represents a groundbreaking discovery in mitochondrial biology as the first identified mitochondrial-derived peptide, independently discovered by three research laboratories in 2001 while investigating neuroprotective factors against Alzheimer’s disease. Encoded within the mitochondrial 16S ribosomal RNA gene (MT-RNR2), this 24-amino acid peptide has demonstrated remarkable cytoprotective properties across multiple organ systems in over two decades of preclinical research. Unlike traditional peptides produced by nuclear genes, Humanin exemplifies a new class of bioactive molecules that originate from mitochondrial DNA, opening an entirely new field of mitochondrial-derived peptide research with implications for aging, neurodegeneration, and metabolic disease.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s structure features a three-turn alpha-helix with no symmetry, and its length varies depending on cellular compartment of synthesis. When produced within mitochondria, Humanin consists of 21 amino acids, while cytoplasmic translation yields the 24-amino acid form. Both variants demonstrate biological activity. The cysteine residue at position 8 is critical for binding to pro-apoptotic proteins, while phenylalanine at position 6 and lysine at position 21 are essential for IGFBP-3 interaction.

Humanin Mechanism of Action

Humanin peptide operates through an intricate network of both intracellular and extracellular signaling mechanisms rather than a single defined receptor pathway. Research indicates that cytoprotective effects stem from dual action: intracellular interactions with apoptotic machinery and extracellular signaling through trimeric receptor complexes. This multi-pathway approach enables Humanin to exert protective effects across diverse cell types and stress conditions, from oxidative damage to ischemic injury.

Primary Cellular Pathways

BAX-Mediated Apoptosis Inhibition – Cell Survival

Studies have demonstrated that Humanin directly binds to BAX (Bcl-2-associated X protein), a pro-apoptotic member of the Bcl-2 family, preventing its translocation to mitochondrial membranes[1]. This mechanism provides:

• Suppression of cytochrome c release from mitochondria, blocking the intrinsic apoptosis cascade
• Direct interaction with truncated BID (tBID) and BIM, additional pro-apoptotic proteins
• Prevention of mitochondrial membrane permeabilization during cellular stress
• Protection against multiple apoptotic stimuli including serum starvation, oxidative stress, and toxin exposure

Research using co-immunoprecipitation confirmed physical interaction between Humanin and BAX, revealing that Humanin interferes with BAX activation rather than affecting BAX expression levels[2].

Trimeric Receptor Complex Signaling – Extracellular Protection

When secreted, Humanin interacts with a trimeric cell surface receptor complex composed of gp130, WSX-1, and CNTFR-alpha, triggering downstream cytoprotective cascades[3]. Key findings include:

• Activation of JAK/STAT3 signaling pathway promoting cell survival gene expression
• Engagement of PI3K/AKT pathway enhancing metabolic protection and insulin sensitivity
• ERK1/2 phosphorylation supporting cellular proliferation and survival
• Tissue-specific receptor expression patterns influencing protection profiles

This extracellular mechanism explains Humanin’s effectiveness when administered systemically, distinct from its intracellular anti-apoptotic effects.

FPRL-1 Receptor Interaction – Cytoprotection

Research has identified formyl peptide receptor-like 1 (FPRL-1, also known as FPR2) as an additional Humanin receptor mediating protective effects[4]:

• Activation of MAPK signaling cascades including ERK1/2
• Modulation of inflammatory responses through receptor-mediated pathways
• Contribution to neuroprotective effects in central nervous system models
• Potential role in leukocyte and immune cell function regulation

IGFBP-3 Binding – Growth Factor Modulation

Humanin binds insulin-like growth factor binding protein 3 (IGFBP-3), modulating its pro-apoptotic activity[5]:

• Neutralization of IGFBP-3-induced cell death in various cell types
• Regulation of IGF-1 bioavailability and signaling
• Influence on cellular response to growth factor stimulation
• Contribution to metabolic and anti-aging effects

Phenylalanine at position 6 and lysine at position 21 are critical for this interaction, as demonstrated through mutational analysis.

STAT3 and Inflammatory Pathway Modulation

Investigations revealed that Humanin treatment influences inflammatory signaling, particularly relevant to age-related diseases[6]:

• Reduction in pro-inflammatory cytokine production including TNF-alpha and IL-6
• Activation of STAT3 phosphorylation promoting anti-inflammatory gene expression
• Systemic inflammation suppression demonstrated in aged mouse models
• Brain-specific anti-inflammatory effects relevant to neurodegeneration

Humanin Research Applications & Key Findings

Neurological Research

Alzheimer’s Disease Models

Extensive preclinical research has examined Humanin’s neuroprotective effects in Alzheimer’s disease contexts, with studies demonstrating protection against multiple AD-related insults[7]. Key findings include:

• Protection against amyloid-beta toxicity in neuronal cell cultures, preventing cell death induced by Abeta1-42, Abeta1-43, and Abeta25-35
• Rescue of neurons from familial AD mutations including APP, presenilin-1, and presenilin-2 variants
• Improved memory performance in triple-transgenic AD mice following chronic Humanin analog administration
• Prevention of memory deficits caused by intracerebroventricular Abeta25-35 injection in rat models

Studies using HNG (a potent Humanin analog with glycine substitution at position 14) showed 1000-fold greater neuroprotective potency than native Humanin[8].

Stroke and Cerebral Ischemia

Research in focal cerebral ischemia models revealed robust neuroprotective effects[9]:

• Significant reduction in infarct volume (40-50%) following middle cerebral artery occlusion in mice
• Decreased neuronal apoptosis in ischemic penumbra regions
• Improved neurological function scores when administered pre- or post-ischemia
• Protection mediated through PI3K/AKT and STAT3 pathways

Both intracerebroventricular and intraperitoneal administration routes demonstrated efficacy, with therapeutic windows extending several hours post-injury.

Cognitive Aging Studies

Investigations in aged mice demonstrated that chronic Humanin administration prevented age-related cognitive decline[10]:

• Improved spatial learning and memory in Morris water maze testing
• Enhanced dendritic complexity and synaptic protein expression in hippocampus
• Prevention of age-associated neuroinflammation in brain tissue
• Genetic variants in Humanin-coding region associated with accelerated cognitive decline in humans

Metabolic Disease Research

Type 2 Diabetes Models

Research in diabetic animal models showed that Humanin improves metabolic parameters through multiple mechanisms[11]:

• Enhanced insulin sensitivity in liver and skeletal muscle following central administration
• Improved glucose tolerance and reduced fasting blood glucose in diabetic rats
• Protection of pancreatic beta-cells from glucotoxicity and apoptosis
• Modulation of hepatic glucose production and peripheral glucose uptake

Humanin infusion into hypothalamus produced systemic metabolic benefits, suggesting central regulation of peripheral insulin action.

Type 1 Diabetes Protection

Studies in non-obese diabetic (NOD) mice revealed protective effects against autoimmune beta-cell destruction[12]:

• Prevention of diabetes onset when administered before disease manifestation
• Partial reversal of hyperglycemia in recent-onset diabetic animals
• Preservation of residual beta-cell mass and function
• Reduction in pancreatic islet inflammation

Cardiovascular Research

Myocardial Protection

Investigations in cardiac injury models demonstrated cardioprotective properties[13]:

• Reduction in myocardial infarct size following ischemia-reperfusion injury in mice
• Protection of cardiomyocytes from doxorubicin-induced cardiotoxicity
• Prevention of age-related myocardial fibrosis with chronic HNG treatment in aged mice
• Improved left ventricular function parameters in heart failure models

Atherosclerosis and Vascular Health

Research in atherosclerosis-prone mouse models showed protective vascular effects[14]:

• Reduced atherosclerotic plaque formation in ApoE-deficient mice on high-cholesterol diet
• Protection of endothelial cells from oxidative stress and apoptosis
• Improved endothelial function and nitric oxide bioavailability
• Reduction in vascular inflammation markers

Aging and Longevity Research

Lifespan and Healthspan Studies

Studies across model organisms revealed associations between Humanin levels and longevity[15]:

• Transgenic Humanin overexpression extended lifespan by approximately 8% in C. elegans
• Chronic HNG administration in aged mice improved healthspan without extending maximum lifespan
• Reduced visceral fat accumulation and increased lean body mass in aged mice
• Circulating Humanin levels elevated in human centenarians compared to age-matched controls

Genetic variants affecting Humanin expression correlated with cognitive aging trajectories in large human cohorts.

Cellular Senescence and Mitochondrial Function

Research examining cellular aging mechanisms demonstrated[16]:

• Humanin levels decline approximately two-thirds in humans over age 80
• Induction of chaperone-mediated autophagy removing damaged proteins
• Protection against mitochondrial dysfunction and oxidative stress
• Species-specific patterns of age-related Humanin decline correlating with healthspan

Humanin Pharmacokinetics & Metabolism

Absorption & Distribution

Humanin exhibits species-dependent pharmacokinetic properties with significant differences between mice and rats documented in published research[17]. Following intraperitoneal injection in rodent models:

• Peak plasma concentrations occur within 10 minutes of administration across species
• Mouse plasma half-life approximately 30 minutes for HNG analog (potent variant)
• Rat plasma half-life exceeds 4 hours, demonstrating substantial species variation
• Tissue distribution studies show highest concentrations in plasma, moderate levels in liver, undetectable in brain and heart

IGFBP-3 binding significantly influences pharmacokinetic profiles, with variants lacking IGFBP-3 interaction demonstrating prolonged circulation times. Wild-type mice treated with HNG (IGFBP-3 binding variant) showed faster clearance than IGFBP-3 knockout mice or when using non-binding analog HNGF6A.

Metabolism & Elimination

The metabolic fate of Humanin remains incompletely characterized, though available research indicates[18]:

• Rapid plasma clearance despite sustained biological effects suggesting tissue retention or downstream signaling persistence
• Likely degradation through peptidase activity, though specific enzymes not definitively identified
• No accumulation detected in chronic dosing studies spanning weeks in rodent models
• Potential for active metabolites contributing to prolonged effects beyond plasma half-life

A notable paradox exists between short plasma half-life (30 minutes to 4 hours depending on species) and prolonged protective effects lasting 24-72 hours after single administration. This discrepancy suggests either tissue accumulation, persistent receptor activation, or downstream signaling cascade amplification.

Excretion Pathways

Limited data on elimination routes indicates[19]:

• Presumed renal excretion of peptide and fragments based on molecular size
• Hepatic metabolism likely contributes to clearance
• No evidence of enterohepatic recirculation
• Clearance rates influenced by circulating binding proteins including IGFBP-3

The role of receptor-mediated endocytosis in Humanin clearance and whether internalized peptide retains biological activity within target cells represent important unanswered questions for therapeutic development.

Humanin Research Protocols & Administration

Dosing in Published Research

Research investigations have employed diverse Humanin doses depending on species, model system, and administration route:

• Mouse studies: 0.1-4 mg/kg typical range (intraperitoneally); 0.1 micrograms (intracerebroventricularly)
• Rat studies: 0.1-1 mg/kg standard range for systemic effects
• C. elegans models: Transgenic overexpression rather than exogenous dosing
• Cell culture studies: 0.1-100 micromolar concentration ranges depending on cell type and assay

Most efficacy studies utilize HNG (high-potency analog with S14G substitution) at doses 1000-fold lower than native Humanin due to enhanced receptor affinity. Chronic administration protocols typically employ twice-weekly intraperitoneal injections in aging studies.

Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to profound differences in pharmacokinetics, receptor expression patterns, metabolic rates, and peptide degradation pathways. Species-specific factors including IGFBP-3 binding capacity, receptor complex expression, and enzymatic degradation systems fundamentally alter both efficacy and safety profiles across organisms.

Administration Routes in Research

Multiple delivery methods have been investigated in preclinical studies:

• Intraperitoneal injection – Most common route in rodent studies; reliable systemic delivery with documented pharmacokinetics
• Intracerebroventricular injection – Used in CNS-focused studies examining direct brain effects and central metabolic regulation
• Intravenous injection – Employed in pharmacokinetic characterization studies; demonstrates rapid clearance
• Subcutaneous injection – Investigated for potential sustained-release applications; absorption kinetics not fully characterized
• Transgenic overexpression – Genetic models in C. elegans and mice producing elevated endogenous Humanin
• Viral vector delivery – Experimental approaches for sustained in vivo Humanin expression

Notably, unlike most peptides, no oral bioavailability studies have been published due to expected rapid degradation by gastrointestinal peptidases.

Common Model Organisms

Humanin has been studied across multiple species and model systems:

• Mice – Primary mammalian model (C57BL/6, IGFBP-3 knockout, transgenic overexpression, disease-specific strains); majority of in vivo data
• Rats – Used in stroke models, diabetes research, and pharmacokinetic studies (Sprague-Dawley, Wistar strains)
• C. elegans – Employed for lifespan extension studies and genetic mechanism investigations
• Cell culture – Neuronal cells (primary cortical neurons, SH-SY5Y), cardiomyocytes, endothelial cells, pancreatic beta-cells, multiple cancer cell lines
• Human subjects – Only observational studies examining endogenous Humanin levels; no interventional trials published

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite over 20 years of intensive preclinical investigation with promising results across multiple disease models, Humanin faces substantial translational challenges that limit progression toward clinical applications.

Lack of Human Clinical Data

The most significant limitation is the complete absence of published human interventional studies:

• No peer-reviewed clinical trials evaluating Humanin or analogs in any disease indication
• No Phase I safety studies establishing human tolerability or dose-response relationships
• No Phase II efficacy trials in target conditions despite preclinical promise
• Human pharmacokinetic parameters, optimal dosing, and safety profile entirely unknown

Only observational studies measuring endogenous Humanin levels in human cohorts have been published, with no therapeutic administration investigated. This represents a critical knowledge gap given the extensive animal efficacy data.

Mechanistic Understanding Gaps

Fundamental aspects of Humanin biology remain incompletely characterized:

• Relative contribution of intracellular versus extracellular mechanisms to protective effects unclear
• Tissue-specific receptor expression patterns and their functional significance not fully mapped
• Whether circulating Humanin crosses blood-brain barrier and accesses CNS targets remains debated
• Active metabolites versus intact peptide contribution to prolonged biological effects unknown
• Cell-type-specific responses and mechanisms of selectivity require clarification

Species Translation Challenges

Substantial species differences create uncertainty for human translation:

• Pharmacokinetic profiles differ dramatically between mice (30-minute half-life) and rats (>4-hour half-life)
• Human pharmacokinetics entirely unpredictable from rodent data
• IGFBP-3 binding effects on distribution may differ across species
• Receptor expression patterns and affinities likely species-dependent
• Optimal analog design for human application remains speculative

Long-Term Safety Considerations

Critical safety questions remain unanswered even in animal models:

• Chronic administration effects beyond several months unstudied in any species
• Impact on cancer cell survival and tumor progression given anti-apoptotic mechanism not thoroughly investigated
• Effects on normal developmental processes, reproduction, and offspring unclear
• Potential for immune responses to exogenous peptide with chronic dosing not characterized
• Interaction potential with medications affecting similar pathways uninvestigated

Regulatory & Competitive Sport Status

FDA Position

Humanin has not received FDA approval for any indication and lacks established regulatory pathway:

• No Investigational New Drug (IND) applications publicly disclosed for clinical development
• Not classified as Generally Recognized as Safe (GRAS)
• Not approved for human therapeutic, diagnostic, or preventive use
• Not legally available for medical compounding in the United States
• No guidance documents specific to mitochondrial-derived peptide development

The FDA would likely classify Humanin as an unapproved new drug requiring comprehensive preclinical and clinical development programs before any therapeutic use.

WADA Status

The World Anti-Doping Agency has not specifically listed Humanin, though relevant classifications may apply:

• Could potentially fall under Section S0 (Non-Approved Substances) given lack of regulatory approval
• Metabolic effects and performance-enhancement potential not thoroughly characterized
• No specific testing protocols or detection methods for anti-doping purposes currently exist
• Competitive athletes should consult WADA guidelines and national anti-doping authorities

Research Classification: Humanin is available only for laboratory research use. It is not intended for human consumption, medical treatment, diagnostic purposes, or veterinary applications. All research must be conducted under appropriate institutional oversight including Institutional Review Board approval for any human subjects research and Institutional Animal Care and Use Committee approval for animal studies.

References

1. Guo, B., Zhai, D., Cabezas, E., Welsh, K., Nouraini, S., Satterthwait, A.C., & Reed, J.C. (2003). Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature, 423(6938), 456-461. PubMed
   
2. Hashimoto, Y., Ito, Y., Niikura, T., Shao, Z., Hata, M., Oyama, F., & Nishimoto, I. (2001). Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein. Biochemical and Biophysical Research Communications, 283(2), 460-468. PubMed
   
3. Kim, S.J., Guerrero, N., Wassef, G., Xiao, J., Mehta, H.H., Cohen, P., & Yen, K. (2016). The mitochondrial-derived peptide humanin activates the ERK1/2, AKT, and STAT3 signaling pathways and has age-dependent signaling differences in the hippocampus. Oncotarget, 7(30), 46899-46912. PubMed
   
4. Yen, K., Lee, C., Mehta, H., & Cohen, P. (2013). The emerging role of the mitochondrial-derived peptide humanin in stress resistance. Journal of Molecular Endocrinology, 50(1), R11-R19. PubMed
   
5. Ikonen, M., Liu, B., Hashimoto, Y., Ma, L., Lee, K.W., Niikura, T., Nishimoto, I., & Cohen, P. (2003). Interaction between the Alzheimer’s survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proceedings of the National Academy of Sciences, 100(22), 13042-13047. PubMed
   
6. Yen, K., Wan, J., Mehta, H.H., Miller, B., Christensen, A., Levine, M.E., Salomon, M.P., Brandhorst, S., Xiao, J., Kim, S.J., Navarrete, G., Campo, D., Harry, G.J., Longo, V., Pike, C.J., Mack, W.J., Hodis, H.N., Crimmins, E.M., & Cohen, P. (2018). Humanin prevents age-related cognitive decline in mice and is associated with improved cognitive age in humans. Scientific Reports, 8(1), 14212. PubMed
   
7. Hashimoto, Y., Niikura, T., Tajima, H., Yasukawa, T., Sudo, H., Ito, Y., Kita, Y., Kawasumi, M., Kouyama, K., Doyu, M., Sobue, G., Koide, T., Tsuji, S., Lang, J., Kurokawa, K., & Nishimoto, I. (2001). A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta. Proceedings of the National Academy of Sciences, 98(11), 6336-6341. PubMed
   
8. Niikura, T., Sidahmed, E., Hirata-Fukae, C., Aisen, P.S., & Matsuoka, Y. (2011). A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. PLoS ONE, 6(1), e16259. PubMed
   
9. Xu, X., Chua, C.C., Gao, J., Hamdy, R.C., & Chua, B.H. (2006). Humanin is a novel neuroprotective agent against stroke. Stroke, 37(10), 2613-2619. PubMed
   
10. Yen, K., Wan, J., Mehta, H.H., Miller, B., Christensen, A., Levine, M.E., Salomon, M.P., Brandhorst, S., Xiao, J., Kim, S.J., Navarrete, G., Campo, D., Harry, G.J., Longo, V., Pike, C.J., Mack, W.J., Hodis, H.N., Crimmins, E.M., & Cohen, P. (2018). Humanin prevents age-related cognitive decline in mice and is associated with improved cognitive age in humans. Scientific Reports, 8(1), 14212. PubMed
    
11. Muzumdar, R.H., Huffman, D.M., Atzmon, G., Buettner, C., Cobb, L.J., Fishman, S., Budagov, T., Cui, L., Einstein, F.H., Poduval, A., Hwang, D., Barzilai, N., & Cohen, P. (2009). Humanin: a novel central regulator of peripheral insulin action. PLoS ONE, 4(7), e6334. PubMed
    
12. Hoang, P.T., Park, P., Cobb, L.J., Paharkova-Vatchkova, V., Hakimi, M., Cohen, P., & Lee, K.W. (2010). The neurosurvival factor Humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice. Metabolism, 59(3), 343-349. PubMed
    
13. Qin, Q., Mehta, H., Yen, K., Navarrete, G., Brandhorst, S., Wan, J., Delrio, S., Lerman, L.O., Cohen, P., & Lerman, A. (2018). Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice. American Journal of Physiology-Heart and Circulatory Physiology, 315(5), H1127-H1136. PubMed
    
14. Oh, Y.K., Bachar, A.R., Zacharias, D.G., Kim, S.G., Wan, J., Cobb, L.J., Lerman, L.O., Cohen, P., & Lerman, A. (2011). Humanin preserves endothelial function and prevents atherosclerotic plaque progression in hypercholesterolemic ApoE deficient mice. Atherosclerosis, 219(1), 65-73. PubMed
    
15. Yen, K., Wan, J., Mehta, H.H., Miller, B., Christensen, A., Levine, M.E., Salomon, M.P., Brandhorst, S., Xiao, J., Kim, S.J., Navarrete, G., Campo, D., Harry, G.J., Longo, V., Pike, C.J., Mack, W.J., Hodis, H.N., Crimmins, E.M., & Cohen, P. (2018). Humanin prevents age-related cognitive decline in mice and is associated with improved cognitive age in humans. Scientific Reports, 8(1), 14212. PubMed
    
16. Cobb, L.J., Lee, C., Xiao, J., Yen, K., Wong, R.G., Nakamura, H.K., Mehta, H.H., Gao, Q., Ashur, C., Huffman, D.M., Wan, J., Muzumdar, R., Barzilai, N., & Cohen, P. (2016). Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging, 8(4), 796-809. PubMed
    
17. Chin, Y.P., Keni, J., Wan, J., Mehta, H., Anene, F., Jia, Y., Lue, Y.H., Swerdloff, R., Cobb, L.J., Wang, C., & Cohen, P. (2013). Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents. Endocrinology, 154(10), 3739-3744. PubMed
    
18. Chin, Y.P., Keni, J., Wan, J., Mehta, H., Anene, F., Jia, Y., Lue, Y.H., Swerdloff, R., Cobb, L.J., Wang, C., & Cohen, P. (2013). Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents. Endocrinology, 154(10), 3739-3744. PubMed
    
19. Yen, K., Lee, C., Mehta, H., & Cohen, P. (2013). The emerging role of the mitochondrial-derived peptide humanin in stress resistance. Journal of Molecular Endocrinology, 50(1), R11-R19. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. Humanin is intended for laboratory research use only.